CA3227854A1 - Novel anti-sirpa antibodies - Google Patents

Novel anti-sirpa antibodies Download PDF

Info

Publication number
CA3227854A1
CA3227854A1 CA3227854A CA3227854A CA3227854A1 CA 3227854 A1 CA3227854 A1 CA 3227854A1 CA 3227854 A CA3227854 A CA 3227854A CA 3227854 A CA3227854 A CA 3227854A CA 3227854 A1 CA3227854 A1 CA 3227854A1
Authority
CA
Canada
Prior art keywords
seq
sequence
antibody
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3227854A
Other languages
English (en)
French (fr)
Inventor
Hongtao Lu
Xiaofeng NIU
Fengli Wang
Chunnian WANG
Jinfeng Zhao
Roumei Xing
Haiying Wang
Jingfeng Yu
Lei Li
Zhihao WU
Rui Gao
Yangsheng QIU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elpiscience Biopharma Ltd
Elpiscience Suzhou Biopharma Ltd
Original Assignee
Elpiscience Biopharma Ltd
Elpiscience Suzhou Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elpiscience Biopharma Ltd, Elpiscience Suzhou Biopharma Ltd filed Critical Elpiscience Biopharma Ltd
Publication of CA3227854A1 publication Critical patent/CA3227854A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cell Biology (AREA)
CA3227854A 2021-07-28 2022-07-28 Novel anti-sirpa antibodies Pending CA3227854A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/109041 2021-07-28
CN2021109041 2021-07-28
CNPCT/CN2022/104562 2022-07-08
CN2022104562 2022-07-08
PCT/US2022/074286 WO2023010100A1 (en) 2021-07-28 2022-07-28 Novel anti-sirpa antibodies

Publications (1)

Publication Number Publication Date
CA3227854A1 true CA3227854A1 (en) 2023-02-02

Family

ID=85087323

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3227854A Pending CA3227854A1 (en) 2021-07-28 2022-07-28 Novel anti-sirpa antibodies

Country Status (9)

Country Link
US (1) US20250270315A1 (https=)
EP (1) EP4377358A4 (https=)
JP (1) JP2024531900A (https=)
KR (1) KR20240039006A (https=)
CN (1) CN118076638A (https=)
AU (1) AU2022317822A1 (https=)
CA (1) CA3227854A1 (https=)
TW (1) TW202313699A (https=)
WO (1) WO2023010100A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120569409A (zh) * 2023-01-18 2025-08-29 科望(苏州)生物医药科技有限公司 靶向sirpa和claudin 18.2的双特异性分子
EP4702053A1 (en) * 2023-04-27 2026-03-04 LaNova Medicines Limited Combination treatment targeting sirpa and claudin 18.2
WO2025140296A1 (zh) * 2023-12-26 2025-07-03 上海宏成药业有限公司 抗dll3抗体或其抗原结合片段及其用途
KR20250164033A (ko) * 2024-05-14 2025-11-24 주식회사 지놈앤컴퍼니 항-bcam 항체 및 이의 컨쥬게이트

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3334757A4 (en) * 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. ANTI-Tigit ANTIBODY
KR20250079073A (ko) * 2018-07-10 2025-06-04 고쿠리츠다이가쿠호진 고베다이가쿠 항 SIRPα 항체
WO2021032078A1 (en) * 2019-08-20 2021-02-25 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-sirpa antibodies
JP7437815B2 (ja) * 2019-12-24 2024-02-26 ラノバ メディシンズ リミテッド 抗ＳＩＲＰαモノクローナル抗体およびその使用

Also Published As

Publication number Publication date
AU2022317822A1 (en) 2024-02-22
EP4377358A1 (en) 2024-06-05
US20250270315A1 (en) 2025-08-28
WO2023010100A1 (en) 2023-02-02
TW202313699A (zh) 2023-04-01
JP2024531900A (ja) 2024-09-03
CN118076638A (zh) 2024-05-24
KR20240039006A (ko) 2024-03-26
EP4377358A4 (en) 2025-12-17

Similar Documents

Publication Publication Date Title
CN112867507B (zh) 新型抗sirpa抗体
AU2018337142A1 (en) Novel bispecific CD3/CD19 polypeptide complexes
WO2020156405A1 (en) Novel bispecific cd3/cd20 polypeptide complexes
US20250270315A1 (en) Novel anti-sirpa antibodies
CA3244178A1 (en) NEW ANTI-TSLP ANTIBODY
US20240043566A1 (en) Bi-functional molecules
US20250368734A1 (en) Novel anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
CA3074524A1 (en) Novel anti-cd19 antibodies
WO2022063272A1 (en) Novel anti-claudin18 antibodies
CA3226306A1 (en) Novel multi-specific molecules
CN116120461B (zh) 新型抗药抗体以及其用途
WO2025119253A1 (en) Novel antibodies that bind to cd3 and lilrb4, and uses thereof
WO2023072182A1 (en) Novel anti-il-36r antibodies
HK40106257A (zh) 新型抗sirpa抗体
CA3075376C (en) Bispecific cd3/cd19 polypeptide complexes
HK40045149A (en) Novel anti-sirpa antibodies
TW202413417A (zh) 新穎抗ｃｄ３抗體及其用途
IL325173A (en) New antibodies targeting CD3 and another target and their uses

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240724

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260112